인간성장호르몬 시장 규모, 점유율, 동향 및 예측 : 용도별, 유통 채널별, 투여 경로별, 지역별(2026-2034년)

The global human growth hormone market size was valued at USD 6.5 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 11.8 Billion by 2034, exhibiting a CAGR of 6.61% during 2026-2034. North America currently dominates the market, holding a significant market share of 42.8% in 2025. The market is growing robustly due to the developed healthcare infrastructure and high incidence of HGH-related disorders like growth hormone deficiencies, Turner syndrome, and Prader-Willi syndrome. Government support in the form of favorable reimbursement policies, availability of leading pharmaceutical firms, including Pfizer and Eli Lilly, and advancements in recombinant DNA methods have also fueled the human growth hormone market share.

The market for human growth hormone (HGH) is witnessing rapid growth due to rising incidences of deficiencies of the growth hormone, including hyposomatotropism. Improvements in biotechnology and recombinant DNA technology have made it possible to produce synthetic HGH, and hence there is improvement in accessibility and affordability. The aging population and the resultant hormone deficiencies due to old age also create a strong demand for HGH therapies. Technological advancements in drug delivery systems, such as long-acting products and easy-to-use devices, improve patient compliance and ease of use. Moreover, increasing awareness among patients and medical practitioners regarding the advantages of HGH therapy helps support market growth. Growing healthcare infrastructure in developing economies provides untapped potential for market penetration. In addition, the growing trend of personalized medication and precision therapeutics enables specialized HGH therapies, maximizing yields and reducing adverse effects.

The United States stands out as a key market disruptor, driven by its advanced health system, robust regulatory system, and cutting-edge pharma landscape. American companies are at the forefront in creating new HGH products, such as long-acting and patient-friendly formulations, that are revolutionizing treatment patterns throughout the world. The proactive regulatory system of the country supports quick approval and commercialization of innovative therapies, leading the way for other global markets. Moreover, high awareness among patients and healthcare professionals also fuels early adoption of new treatments. Heavy investment in research and biotechnology further accelerates product innovation and competition, forcing global players to catch up with US standards. The incorporation of personalized medicine and digital health solutions also improves treatment accuracy and patient compliance. Consequently, the US shapes product development while also altering market expectations, positioning it as a trendsetter and a disruptor in the global HGH market space.

HUMAN GROWTH HORMONE MARKET TRENDS:

Growing Emphasis on Personalized and Preventive Therapies and Other Disorders

One of the most prominent trends transforming the human growth hormone (HGH) industry is growing emphasis on personalized and preventive healthcare methods. As medical science continues to evolve, treatments are departing from generic protocols to customized regimens specific to a patient's genetics, habits, and individual hormonal deficiencies. This trend is especially significant in the HGH market, where treatment duration and dosages can dramatically differ based on the patient's age, condition, and metabolic response. Doctors are increasingly using diagnostic tools and digital monitoring technologies to refine hormone therapies, producing improved results with fewer side effects. Preventive measures are also making inroads, with HGH being investigated for deficiency disorders, and also for age-related degeneration, trauma recovery, and chronic fatigue. Moreover, the increasing prevalence of Turner syndrome and other growth-related disorders is one of the key factors driving the growth of the market. Turner syndrome is a chromosomal disorder that primarily affects females and is characterized by complete or partial loss of X chromosomes, occurring in approximately one in 2,500 female babies. Growth hormones are often administered to reverse some of the symptoms of this disease, thereby increasing the demand for HGH drugs across the globe. These expanded uses are broadening the market scope while responding to increasing consumer interest in wellness and longevity solutions, further fueling the human growth hormone market growth.

Technological Advances in Drug Delivery Systems

Several advancements in drug delivery systems are another principal trend propelling growth and innovation in the market for human growth hormone. Conventional HGH therapy was historically in the form of frequent, even daily injections, which imposed compliance challenges among pediatric and aged patients. The solution to this is the ongoing investment by the pharmaceutical industry to develop long-duration formulations, pen devices, and even transdermal patches and auto-injectors. These technologies are considerably improving patient convenience and treatment burden reduction, making HGH therapy more available and less daunting. Better drug delivery technology also improves stability in terms of hormone levels in the blood, reducing side effects and improving therapeutic efficacy. The trend is therefore an extension of a general shift toward patient-centered product design in the biopharmaceutical market. Moreover, with the rise in competition, pharmaceutical companies are focusing on ease of use and patient satisfaction as differentiators. Ultimately, these advances in technology are enhancing treatment outcomes, while also transforming user experience and broadening the market's appeal across a wide range of patient segments.

Expansion into Non-Traditional and Wellness Applications

The market is expanding beyond conventional medical applications into wider wellness, sports, and aesthetic uses, as per the human growth hormone market forecast. Although HGH is still an important therapy for growth hormone deficiency and Turner syndrome, its perceived virtues in anti-aging, muscle building, and metabolic well-being are creating waves in lifestyle and elective healthcare markets. Clinics that provide hormone replacement therapy are becoming increasingly popular among older age groups that aim to stay youthful and physically fit. While such applications are usually contentious and subject to regulatory oversight, demand remains strong, driven by increasing awareness and interest in longevity and quality of life. This is creating new market dynamics, as conventional pharmaceutical companies find themselves competing with private wellness clinics and integrative medicine practices. The convergence of medical necessity and lifestyle enhancement is hence giving rise to several opportunities. Consequently, the HGH industry is transforming itself into a highly sophisticated ecosystem as it is governed by both clinical necessities and consumer desires.

HUMAN GROWTH HORMONE INDUSTRY SEGMENTATION:

Analysis by Application:

• Growth Hormone (GH) Deficiency
  • Adult GH Deficiency
  • Pediatric GH Deficiency
• Turner Syndrome
• Idiopathic Short Stature (ISS)
• Prader-Willi Syndrome (PWS)
• Small for Gestational Age
• Others

Growth hormone (GH) deficiency stands as the largest component in 2025. Growth hormone deficiency continues to dominate the human growth hormone (HGH) industry's leading applications segment, spearheaded by the proven clinical application and steady demand for both pediatrics and adult patient populations. GH deficiency among children can cause dwarfism, delayed puberty, and other aspects of developmental shortcomings, thus prompt diagnosis and management are imperative. Among adults, GH deficiency primarily manifests as lost muscle mass, lethargy, and declining metabolic function. The obvious therapeutic advantage of HGH in treating these symptoms guarantees long-term market demand. Physicians prescribe HGH therapy as routine treatment, underpinned by robust clinical guidelines and long-term outcome evidence. This segment also enjoys the advantage of ongoing research, which continues to optimize treatment protocols and enhance patient monitoring. The diagnosability of GH deficiency, along with improvements in diagnostic equipment and greater recognition by healthcare practitioners, reinforces its position as the cornerstone application supporting steady growth as observed throughout the human growth hormone market report.

Analysis by Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Hospital pharmacy leads the market with around 47.9% of market share in 2025. Hospital pharmacies are the primary channel of distribution in the human growth hormone (HGH) market because they can provide safe, regulated, and consistent access to hormone therapy. These pharmacies are usually the first point of dispensing for patients with complicated or chronic endocrine disorders, such as growth hormone deficiency. Hospitals provide an ordered setting for prescribing, administration, and patient supervision, a situation necessary for drugs requiring stringent dosing and monitoring. They are also generally centers for consolidated master plans involving treatment under specialists that endocrinologists and pediatricians coordinate, another guaranteeing element for them as a supplier of HGH. Moreover, hospitals are patient education centers and programs assuring maximization in therapeutic intervention. With stricter regulation and the necessity for high-standard storage and handling of biologics such as HGH, hospital pharmacies are adequately positioned to achieve compliance levels. Their place within larger healthcare delivery systems ensures that they are a reliable and trusted channel, playing an important role in ensuring the stability and growth of the HGH market.

Analysis by Route of Administration:

• Intravenous
• Intramuscular
• Subcutaneous
• Oral

Subcutaneous leads the market with around 33.7% of market share in 2025. Subcutaneous administration is the most predominant mode of administration in the human growth hormone (HGH) industry because it is effective, convenient, and patient-compliant. Subcutaneous injections are unlike intravenous (IV) injections, which must be administered under clinical observation, as they can be self-administered by patients in their own homes, thus the best for maintenance hormone therapy. This technique consists of injecting HGH into the fat tissue directly under the skin, so it can be slowly and steadily absorbed into the body. It is also less intrusive than other techniques, with lower risks of complications like infection or damage to the blood vessels. With time, improvements in the injection equipment, including pre-filled syringes, auto-injectors, and pen devices, have further simplified subcutaneous administration. These innovations increase patient comfort, simplify the treatment process, and enhance compliance. Considering these factors, subcutaneous injections are the favored and most adopted mode of administration for HGH treatments, fueling growth within the HGH market.

Regional Analysis:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

In 2025, North America accounted for the largest market share of over 42.8%. North America is the leading regional segment in the worldwide human growth hormone (HGH) market, fueled by a mix of sophisticated healthcare infrastructure, strong research and development activities, and a high incidence of growth hormone deficiencies. The United States, especially, is instrumental, with a major market share due to its well-established healthcare systems and pervasive availability of HGH therapies. This dominance is complemented by supportive reimbursement policies and government actions that enable patient access to treatments that are essential. Major pharmaceutical corporations headquartered in North America, including Pfizer and Eli Lilly, drives the market growth by ensuring ongoing innovation and the establishment of new HGH products. While, these innovations enhance the effectiveness of treatments, they also optimize patient compliance and quality of life. The region's dedication to healthcare excellence guarantees a consistent demand for HGH treatments, cementing its status as the top market segment. In the future, North America's market share is likely to continue its upward growth, driven by continued investment in healthcare infrastructure and growing public awareness about growth hormone deficiency. With the region continuing to dominate both in terms of market size and innovation, it also sets the standard for HGH therapy practice globally.

KEY REGIONAL TAKEAWAYS:

UNITED STATES HUMAN GROWTH HORMONE MARKET ANALYSIS

In 2025, the United States accounted for over 91.80% of the human growth hormone market in North America. The United States human growth hormone (HGH) market is witnessing sustained growth, driven by increasing awareness about hormone-related disorders and a growing emphasis on physical health and wellness. An increase in the elderly population, with the count of Americans aged 65 and above expected to reach 82 million by 2050, is fueling the rising demand for hormone replacement therapies (PRB). Additionally, the expanding use of HGH in managing conditions associated with growth hormone deficiency and improved diagnostic capabilities is fueling market demand. Supportive healthcare infrastructure, along with a rise in specialized treatment centers, further boosts market growth. Technological advancements in drug delivery methods and increasing healthcare expenditure are enhancing accessibility and treatment adherence. The expanding scope of therapeutic applications beyond traditional uses is also stimulating market interest. Investment in medical research, regulatory support, personalized medicine, preventive healthcare, fitness consciousness, hormone therapy uses, digital health integration, and early diagnosis awareness are driving market growth.

EUROPE HUMAN GROWTH HORMONE MARKET ANALYSIS

The human growth hormone market in Europe is expanding steadily due to increased recognition of endocrine disorders and broader acceptance of hormonal therapies. An aging demographic and the growing focus on improving quality of life are fueling the demand for growth hormone treatment options. The European Pharmaceutical Review states that biosimilar competition in Europe has significantly increased patient access to key biological medicines, with healthcare budget reductions amounting to €56 billion across Europe and approx. €6 billion in 2024 alone. This trend supports the wider adoption of growth hormone therapies by making them more affordable and accessible. The market for hormone therapies is thriving due to advancements in healthcare systems, advanced diagnostic tools, research and development efforts, public health initiatives, digital technology integration, continuous medical education programs, and the growing perception of hormone therapies as part of overall wellness strategies. With rising healthcare investments and a focus on preventive care, the market is poised for continued expansion.

ASIA PACIFIC HUMAN GROWTH HORMONE MARKET ANALYSIS

The Asia Pacific human growth hormone market outlook is experiencing robust growth, fueled by increasing healthcare awareness and rising demand for hormone-based therapies. Improved healthcare access and infrastructure across developing regions are enhancing diagnosis and treatment rates. A growing population and a heightened focus on child development are also contributing to market expansion. According to the India Brand Equity Foundation, the Indian healthcare market, valued at USD 110 Billion in FY16, is now projected to reach USD 638 Billion by FY25, further indicating the growing healthcare needs in the region. The adoption of advanced medical technologies and an escalating interest in personalized treatment are strengthening therapeutic approaches. Enhanced government health initiatives and greater public awareness about hormone-related disorders are accelerating market activity. Furthermore, the demand for better quality of life and rising investment in medical innovation are supporting long-term growth. The market outlook remains positive, driven by changing lifestyle patterns and increased health consciousness across urban populations.

LATIN AMERICA HUMAN GROWTH HORMONE MARKET ANALYSIS

The Latin American human growth hormone market is expanding due to increased public awareness, healthcare coverage, and improved medical infrastructure. The market is driven by a rising focus on growth and developmental health, hormone therapy adoption, and general wellness promotion. Additionally, the region is benefitting from continuous initiatives aimed at improving healthcare service delivery, as Brazil's local manufacturing of medical supplies satisfies 42% of the population's requirements. With the New Industry Brazil (NIB) initiative, the government seeks to elevate this percentage to 50% by 2026 and to 70% by 2033, which will enhance market potential by facilitating access to therapeutic solutions. These combined initiatives are setting the area up for ongoing expansion in the HGH market.

MIDDLE EAST AND AFRICA HUMAN GROWTH HORMONE MARKET ANALYSIS

The Middle East and Africa human growth hormone market is expanding due to increased awareness about endocrine health, improved healthcare access, investments in medical facilities, health education, demand for advanced therapies, and long-term wellness focus. This growth is fueled by increased support for health infrastructure. Additionally, the growing medical tourism sector in the region plays a significant role in market expansion. With ongoing developments in healthcare provision and a shift toward preventive care practices, the market is poised for further advancement. These factors collectively contribute to the promising outlook of the region's HGH market.

COMPETITIVE LANDSCAPE:

Major companies in the human growth hormone market are developing growth through different strategic initiatives, such as product development innovation, strategic alliances, and increased patient accessibility programs. Major pharmaceuticals like Novo Nordisk, Pfizer, Eli Lilly, and Merck are investing in developing future-generation HGH products, including long-acting or sustained-release products, that decrease the number of injections and increase patient compliance. These innovations are intended to make treatment more convenient for pediatric as well as adult patients, resulting in better therapeutic results. These firms also invest heavily on research and development to identify new uses for HGH, such as in anti-aging and metabolic health, broadening the scope of the market beyond conventional deficiency treatments. Additionally, key players are establishing strategic alliances and partnerships with healthcare professionals, academic centers, and research centers to increase market presence and widen clinical evidence backing HGH treatments. These partnerships facilitate quicker product development and lead to bringing new solutions to the market more efficiently. In order to enhance patient accessibility, firms are collaborating with payers and regulatory agencies to rationalize approval processes and make HGH therapies widely available and affordable. Consequently, these initiatives are driving market growth, improving the overall efficacy of HGH treatment, and responding to the heterogeneous needs of the patient base.

The report provides a comprehensive analysis of the competitive landscape in the human growth hormone market with detailed profiles of all major companies, including:

• Eli Lilly and Company
• EMD Serono Inc.
• F. Hoffmann-La Roche AG
• Ferring B.V.
• Genentech Inc.
• Ipsen
• Merck KGaA
• Novartis AG
• Novo Nordisk
• Pfizer Inc.
• Sandoz

Key Questions Answered in This Report

1. How big is the human growth hormone market?

2. What is the future outlook of human growth hormone market?

3. What are the key factors driving the human growth hormone market?

4. Which region accounts for the largest human growth hormone market share?

5. Which are the leading companies in the global human growth hormone market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Human Growth Hormone Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Application

• 6.1 Growth Hormone (GH) Deficiency
  • 6.1.1 Market Trends
  • 6.1.2 Major Types
    • 6.1.2.1 Adult GH Deficiency
    • 6.1.2.2 Pediatric GH Deficiency
  • 6.1.3 Market Forecast
• 6.2 Turner Syndrome
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Idiopathic Short Stature (ISS)
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Prader-Willi Syndrome (PWS)
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Small for Gestational Age
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Others
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast

7 Market Breakup by Distribution Channel

• 7.1 Hospital Pharmacy
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Retail Pharmacy
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Online Pharmacy
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Route of Administration

• 8.1 Intravenous
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Intramuscular
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Subcutaneous
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Oral
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Eli Lilly and Company
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 EMD Serono Inc.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
  • 13.3.3 F. Hoffmann-La Roche AG
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 SWOT Analysis
  • 13.3.4 Ferring B.V.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
  • 13.3.5 Genentech Inc.
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 SWOT Analysis
  • 13.3.6 Ipsen
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
  • 13.3.7 Merck KGaA
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
  • 13.3.8 Novartis AG
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
  • 13.3.9 Novo Nordisk
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
  • 13.3.10 Pfizer Inc.
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis
  • 13.3.11 Sandoz
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio